DFP-14927, PEG-drug conjugate with antitumor efficacy in pancreatic cancer models
Aug. 1, 2023
Researchers from Delta-Fly Pharma Inc. presented preclinical data for DFP-14927, a polyethylene glycol (PEG)-conjugate of a deoxycytidine analogue, being developed as a potential anticancer agent.
